Although March brought on tough times for top stocks in the medtech industry, April is already showing signs of a rebound. The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the index hitting its lowest […]
Illumina Inc.
DTW Podcast: Earnhardt shares how Abbott shifted gears to counter pandemic; Grail still looks to upend oncology
This week, we’ll talk with Abbott’s medical devices EVP Lisa Earnhardt about how the life sciences giant pivoted during the pandemic. Earnhardt shares what programs were given greater priority when the lockdown’s impact became clear and why the company performed so well in one of its key businesses. We also explore this week’s news that […]
Illumina postpones $8B Grail deal amid FTC challenge
Illumina (NSDQ:ILMN) has delayed its proposed $8 billion acquisition of Grail amid a FTC challenge. The companies have agreed to postpone the planned purchase until after Sept. 20 while the FTC challenges the deal, according to a temporary restraining order issued out of U.S. District Court in the District of Columbia. News of Illumina’s agreement […]
Illumina vows to pursue Grail purchase despite FTC challenge
Illumina (NSDQ:ILMN) announced today that it disagrees with and will oppose the FTC’s challenge to its acquisition of Grail. San Diego-based Illumina announced in September that it entered into an agreement to acquire the cancer detection startup that spun out from the company four years ago for cash and stock consideration of $8 billion. founded […]
Illumina to acquire Grail for $8B, expands cancer early detection
Illumina (NSDQ:ILMN) announced today that it entered into an agreement to acquire Grail for cash and stock consideration of $8 billion. Last week, it was reported that Illumina was looking to purchase the cancer detection startup that spun out from the company four years ago and the companies confirmed that to be true today. Grail was […]
Illumina may buy back Grail
Illumina (NSDQ:ILMN) may acquire Grail for more than $8 billion — four years after it spun out the cancer detection startup. That’s according to a Bloomberg report out yesterday, which cited people familiar with the matter. Analysts told Bloomberg that the acquisition would put Illumina — a giant in the DNA sequencing space — in direct […]
NIH to boost COVID-19 testing capabilities
The National Institutes of Health announced a $129.3 million plan to support scaling and manufacturing for COVID-19 tests. As part of its Rapid Acceleration of Diagnostics (RADx) initiative, NIH is awarding contracts to nine companies for their technologies that include portable point-of-care tests for immediate results and high-throughput laboratories that can produce results in 24 […]
Illumina gains FDA EUA for sequencing-based COVID-19 test
Illumina (NSDQ:ILMN) announced that it received FDA emergency use authorization (EUA) for its COVIDSeq sequencing-based COVID-19 diagnostic test. COVIDSeq uses upper respiratory specimens, such as a nasopharyngeal or oropharyngeal swab, and delivers sample receipt to result in 24 hours with the NovaSeq 6000 sequencing system, according to a news release. Illumina’s high-throughput, in vitro diagnostic test […]
Bristol-Myers Squibb, Illumina to develop companion diagnostics for immunotherapies
Bristol-Myers Squibb (NYSE:BMY) is joining forces with Illumina (NSDQ:ILMN) to develop and commercialize diagnostic tests to support Bristol’s portfolio of cancer drugs. The companies announced last week that they plan to develop an assay to measure predictive genomic biomarkers, like tumor mutation burden, that could help doctors identify patients that will benefit from Bristol’s immunotherapies. Get the full […]
Illumina, Loxo Oncology partner for next-gen pan-cancer companion diagnostics
Illumina (NSDQ:ILMN) and Loxo Oncology (NSDQ:LOXO) are teaming up to develop a multi-gene panel for broad tumor profiling. The two companies ultimately hope to sell a next-gen sequencing-based companion diagnostic that will boast a pan-cancer indication. Illumina and Loxo plan to seek approval for a version of Illumina’s TruSight Tumor 170 test as a companion […]
Skyline Medical to take 20% stake in Helomics, license Illumina’s gene sequencing tech
Fresh from its purchase of a 20% stake in joint venture partner Helomics, Skyline Medical (NSDQ:SKLN) said today that it inked a deal to license the MiSeqDx next-generation sequencing technology from Illumina (NSDQ:ILMN). Yesterday Minneapolis-based Skyline said it agreed to buy a lump of convertible shares representing 20% of Helomics, in exchange for 1.1 million newly issued SKLN shares, which […]
